TGI 2
Alternative Names: NM1F; TGI-2; TGI-2/NM1FLatest Information Update: 26 May 2023
Price :
$50 *
At a glance
- Originator TG ImmunoPharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Colorectal cancer; Malignant melanoma; Ovarian cancer; Triple negative breast cancer
- Preclinical Solid tumours
Most Recent Events
- 13 Apr 2023 Phase-I clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Late-stage disease) in USA (Parenteral) (NCT05746897)
- 13 Apr 2023 Phase-I clinical trials in Colorectal cancer (Monotherapy, Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT05746897)
- 13 Apr 2023 Phase-I clinical trials in Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT05746897)